Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.

Revenue
+41.2%
EPS
−3.67%
Free cash flow
+79.0%

Quarter to September 2026, against a year earlier

164.51 4.75 +2.97%
Market cap
$16.2B
P/E
23.6×
Fwd P/E
20.6×
Dividend yield
—
F-score
7/9
Altman Z
7.80
Beneish M
−2.64
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— 3 6 7 5 4 6 6 8 7
P/E ratio
0.00 0.00 324.59 268.73 21.98 89.65 74.58 51.86 40.38 29.43
P/S ratio
92.53 39.55 14.28 12.49 8.53 7.11 7.73 6.82 5.82 4.93
Altman Z-Score
35.68 7.56 7.24 8.65 9.70 7.62 11.59 8.70 8.83 7.80
Altman Z″-Score (non-manufacturers)
(0.53) (0.97) 1.66 (0.12) 4.35 3.70 5.40 4.58 5.61 6.21
P/FCF ratio
0.00 0.00 84.09 74.42 41.01 34.56 35.63 35.59 24.60 18.85
Beneish M-Score
— — (1.52) (1.75) (1.55) (2.60) (2.15) (1.68) (2.23) (2.64)
P/Operating CF
(106.00) 172.16 127.57 100.99 94.43 1,918.35 80.45 104.21 56.51 36.33
P/B ratio
10.65 18.77 13.40 15.46 7.92 5.86 6.74 5.77 5.29 4.34
EV/Sales
84.07 38.72 14.54 12.24 8.44 7.11 7.38 6.57 5.60 4.61
EV/EBITDA
0.00 0.00 109.92 96.46 45.72 58.40 40.97 48.80 23.07 20.71
EV/FCF
(27.62) (67.54) 85.67 72.91 40.55 34.60 34.04 34.27 23.66 17.61
Current Ratio
10.21 10.20 8.36 1.47 5.45 3.96 2.70 2.45 3.40 3.39
Net Debt/EBITDA
2.15 1.27 (4.40) (5.83) (2.50) (2.72) (3.69) (4.06) (1.88) (2.33)
Debt/Equity
0.00 0.99 0.81 0.14 0.28 0.24 0.00 0.00 0.00 0.00
ROE
(38.17%) (41.50%) 4.95% 6.62% 46.20% 7.17% 10.03% 12.68% 14.16% 16.38%
ROA
(33.60%) (24.10%) 2.33% 3.22% 26.79% 4.71% 6.96% 8.89% 9.79% 11.46%
ROIC
(1,130.99%) (36.36%) 10.53% 84.62% 15.84% 6.42% 21.66% 13.06% 23.56% 21.83%
Return on Tangible Assets
(49.28%) (27.88%) 3.09% 12.03% 46.59% 11.41% 15.86% 24.41% 26.26% 25.61%
Average Days of Receivables
0.00 70.29 46.44 58.63 54.83 59.73 85.81 84.97 74.25 87.64
Earnings Yield
(4.19%) (2.06%) 0.31% 0.37% 4.55% 1.12% 1.34% 1.93% 2.48% 3.40%
Free Cash Flow Yield
(3.29%) (1.45%) 1.19% 1.34% 2.44% 2.89% 2.81% 2.81% 4.07% 5.31%
Free Cash Flow per Share
(1.27) (1.15) 0.85 1.44 2.34 2.46 3.37 3.70 5.55 7.52
Book value per Share
3.63 4.22 5.33 6.95 12.10 14.52 17.83 22.85 25.79 32.69
Free Cash Flow
(110.28) (101.26) 76.60 132.30 217.60 233.10 322.90 361.60 557.20 748.70
EV/EBIT
0.00 0.00 178.33 133.42 54.14 78.68 44.14 49.39 23.11 21.30
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026